Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Issue and repurchase of class C shares for incentive program

Medicover AB’s (publ) board of directors has today resolved to issue and immediately repurchase 2,400,000 new class C shares. The shares are issued and repurchased in accordance with the terms of the long term performance-based share programs “the Plan 2017” and “the Plan 2018” for group management and other key-employees, as approved by the extraordinary general meeting held on 31 March 2017 and by the annual general meeting held on 26 April 2018. Nordea Bank Abp will subscribe for all issued C shares at a subscription price of EUR 0.2 per share. All issued C shares will be

After a period of high growth and with listing on Nasdaq Stockholm accomplished, there now follows a consolidation phase

INTERIM REPORT 1 January – 30 September 2018 ROLLING 12 MONTHS 01/10/2017 – 30/09/2018                     · Pro rata – sales: SEK 900.6 million (723.2) · Net sales: SEK 1,084 million (990.0) · Operating profit before depreciations (EBITDA): SEK 24.2 million (19.2) · Operating profit EBIT SEK 5.5 million (3.6) · Operating margin, pro rata: 0.6% (0.5%) · Operating margin: 0.5% (0.4%) · Earnings per share:  SEK -0.30 (0.18) THIRD QUARTER 2018 · Pro rata sales: SEK 148.8 million (130.9) · Net sales: SEK 170.2 million (146.1) · Operating loss before

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018

Increased focus where we can create the most valueJuly – SeptemberSignificant events during the quarter · Positive top-line joint structure outcomes were reported from the MIV-711 osteoarthritis phase II extension study (MIV-711-202). Treatment with MIV-711 over a total 12 months resulted in a continuing treatment effect on joint bone area growth and prevention of cartilage degradation. · The first patient was enrolled and dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC). · Dr. Linda Basse was

INTERIM REPORT 1 JULY– 30 SEPTEMBER 2018

“We are concluding yet another intense quarter for Episurf Medical. We are continuing to deliver on our strategy, and the activity level is high across our business. We are approaching the completion of two of our most important milestones ever, namely the approval to start a clinical trial in the US and the launch of an individualised ankle implant. We are improving our results during the quarter, driven both by increased revenues and lowered operating expenses", says Pål Ryfors, CEO Episurf Medical. Third quarter 2018 compared to 2017, Group » Group net sales increased by 86.7%

Evolution launches Infinite Blackjack with unlimited seats for players

Evolution Gaming, leading provider of Live Casino solutions, has announced the launch of its first totally scalable Live Blackjack table. Evolution’s Live Infinite Blackjack adds a unique twist of the traditional Blackjack game to the company’s extensive live table games portfolio, while providing an unlimited number of seats at a single Blackjack table.Available on desktop, tablet and smartphone, Infinite Blackjack is an innovative solution that guarantees players a Blackjack seat at all times, in contrast to traditional Blackjack tables where only seven seats are available at each table.

Interim Report January – September 2018

Increased order intake and acquisition of I-Window generate a strong tender baseThird quarter of 2018 ·  Net sales for the period amounted to SEK 0.0 (3.3) million and earnings to SEK -12.5 (-13.5) million, which corresponds to earnings per share of SEK -0.30 (-0.58).   ·  Cash and cash equivalents on September 30 amounted to SEK 12.5 million.  ·  In August, the assets of I-window International AB were acquired to broaden the product portfolio and strengthen the sales organization. ·  Order intake amounted to SEK 10 million during the quarter. Total tender base, including the

Interim report Pricer AB January-September 2018

Record high net sales for an individual quarter and continued strong order intake Third quarter 2018 · Net sales of SEK 406.0 M (193.8), an increase of 110 percent compared to the same period of last year  · Operating profit of SEK 31.0 M (20.5), corresponding to an operating margin of 7.6 percent (10.6)  · Order intake of SEK 286 M (234), an increase of 22 percent compared to the same period of last year  · The order backlog increased to SEK 338 M (144), most of which is expected to be invoiced before the end of 2018  · Profit for the period amounted to SEK 27.4 M (16.1)

Scandinavian Enviro Systems AB (publ) conducts a Rights Issue of approximately MSEK 106 and a change of business description

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. The Board of Directors in Scandinavian Enviro Systems AB (publ) ("Enviro" or "the Company") has, subject to the subsequent approval of the shareholders' meeting, resolved to issue shares and warrants (units) with preferential rights for the Company's existing shareholders ("Rights Issue"). The Offering consist of a maximum of 264,038,280 new shares and a maximum of 264,038,280 warrants.The resolution

Klaria signs agreement for EU grant worth ca. 21 MSEK to take migraine product to market

Klaria Pharma Holding AB (publ) announces that the company has finalized and signed the agreement for the grant of 21 MSEK in total from the EU Horizon 2020 program. The grant will, as announced earlier, be used to finalize the development and commerzialisation of KL-00119, the company’s leading candidate for treatment of acute migraine-related pain.The EU grant, with agreement number 829615, is expected to cover the costs for all of the remaining activities in the KL-00119 project up to and including a potential market registration in Europe, the United States and Canada. The remaining

XMReality AB (publ), Interim Report, July–September 2018

Yet another quarter when all signs point to growth for XMReality, with strong increases in order intake and billing. Several new and exciting collaborations have begun and strategically important new software features have been developed. After the end of the quarter, an extraordinary general meeting resolved execute a directed new issue to raise capital of approximately SEK 21 million before issue costs.The quarter: July-September 2018 · Net sales amounted to SEK 2,766 thousand (1,635). · Costs totalled SEK -10,026 thousand (-8,605). · The net loss was SEK -5,791 thousand (-5,

Stora Enso’s Interim Report January–September 2018: Another quarter of profitable growth

STORA ENSO OYJ, Helsinki, FinlandINTERIM REPORT 26 October 2018 at 9.30 EESTQ3/2018 (year-on-year) · Sales increased 3.0% to EUR 2 585 (2 509) million, making Q3 the seventh consecutive quarter of sales growth. The growth was primarily due to favourable prices and active product mix management. · Operational EBIT increased 23.4% to EUR 358 (290) million, due to favourable prices and active product mix management. · Balance sheet continued to strengthen, and net debt was reduced by EUR 304 million. The net debt to operational EBITDA ratio improved significantly to 1.1 (1.6). ·

Microsoft to lease offices in Skanska’s Campus 6, Bucharest, Romania

Microsoft has leased 23,000 square meters of office space and 500 parking spaces in Skanska’s Campus 6, in Bucharest, Romania. The start date of the lease is in the third quarter of 2020.At completion, in 2022, the Campus 6 office complex will comprise four buildings that offer a total leasable area of approximately 81,000 square meters. The buildings will be LEED Gold and WELL certified. Skanska is one of the leading development and construction companies in Europe. Outside the Nordics, the company has European operations in building construction and civil engineering in Poland, Czech

INVISIO Interim Report January–September 2018: Expected orders behind inventory build-up

Stockholm, October 26, 2018 CEO comment”In many parts of the world we see continued investment in communication and safety, as well as increasing defense budgets, and we expect continuous strengthening of our position as a leading supplier. In the past quarter we have had a weaker order intake due to procurements at irregular intervals and the long lead times in the industry. The increase in inventories was to enable rapid delivery on orders we have good reason to expect”, says Lars Højgård Hansen, CEO of INVISIO.July–September 2018 · Revenue: SEK 80.9 m (75.5) · Gross profit:

Heliospectra AB (publ) Interim Management Statement January - September 2018

(GOTHENBURG, Sweden/SAN FRANCISCO, CA, October 26th, 2018) –Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for controlled environments horticulture, today present their Interim Management Statement for January to September 2018.Turnover and Profit/Loss January - September · Order intake amounted to SEK 38,022 (28,082) thousand · Net sales amounted to SEK 34,287 (19,550) thousand · Operating profit/loss amounted to SEK -21,231(-25,611) thousand  · Profit/loss after tax was SEK -21,273 (-25,701) thousand

Fujitsu and Ericsson team up on 5G partnership

Tokyo, Japan and Stockholm, Sweden, October 26, 2018: Fujitsu Limited and Ericsson (NASDAQ: ERIC) have entered an agreement to deliver end-to-end 5G network solutions and related services under a strategic partnership. The two companies are joining forces to develop this based on their combined portfolios – spanning radio access and core network – for the dynamic 5G market in Japan, connecting communications service providers to the global 5G ecosystem. The two companies aim to initially provide systems and solutions for the Japanese market, and seek to further expand their collaboration

Interim Report January – September 2018

Highlights from the third quarter · In local currencies, sales increased by 10 percent for the third quarter. Reported sales increased by 16 percent to 3,388 MSEK (2,915). · In local currencies, operating profit from product segments1) increased by 13 percent for the third quarter. Reported operating profit from product segments increased by 19 percent to 1,317 MSEK (1,104). · Operating profit amounted to 1,305 MSEK (1,088) for the third quarter. · Profit after tax amounted to 959 MSEK (753) for the third quarter. · Earnings per share increased by 32 percent to 5.55 SEK (4.22)

Report for the third quarter 2018

Financial and operating highlights 3Q 2018 (3Q 2017 in brackets): · Operating revenues were NOK 2 008 million (NOK 2 180 million) · EBITDA (operating result before depreciation, impairment, result from associates, finance and tax)was NOK 264 million (NOK 572 million) · Year on year EBITDA improvement of NOK 101 million apart from Offshore drilling · Depreciation was NOK 658 million (NOK 652 million) · Impairment was NOK 182 million (NOK 16 million · EBIT (operating result) was NOK - 576 million (NOK - 96 million · Net finance was NOK - 144      million (NOK - 208

Ratos AB: CEO Peter Nilsson to leave Speed Group

Press release 26 October 2018 Peter Nilsson is stepping down from his role as CEO of Ratos's subsidiary Speed Group. The company's CFO, Anders Appelqvist, has been appointed Acting CEO until a permanent CEO has been recruited. Outgoing CEO Peter Nilsson was initially a member of Speed Group's Board of Directors before taking over as CEO in autumn 2016. Peter is now leaving the company and Anders Appelqvist, who currently serves as the company's CFO, has been appointed Acting CEO. Anders will take office effective immediately and the process to recruit a permanent replacement has begun.

Acando Interim report January 1-September 30, 2018

Third quarter, July 1–September 30, 2018 · Net sales totaled SEK 590 m (518) · Operating profit amounted to SEK 31 m (27) · Operating margin was 5.2% (5.2) · Profit after tax was SEK 32 m (17) · Earnings per share were SEK 0.30 (0.17) Accumulated, January 1–September 30, 2018 · Net sales totaled SEK 2,029 m (1,753) · Operating profit amounted to SEK 181 m (157) · Profit before non-recurring items SEK 186 m · Operating margin was 8.9% (8.9) · Profit after tax was SEK 147 m (113) · Earnings per share were SEK 1.41 (1.09) · Cash and cash equivalents

Alligator Bioscience AB Interim Report January-September 2018

The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator’s research and development.Significant events July-September • Preclinical development of ATOR-1015 completed. Application for Clinical Trial Authorization submitted. • New preclinical data supports the favorable safety profile of the 4-1BB antibody ATOR-1017.  Events after the end of the period • James P. Allison and Tasuku Honjo to receive the Nobel Prize for their pioneering work in cancer immunotherapy, directly linked to ATOR-1015. • Frances H. Arnold, George P. Smith and Sir

There are no items matching the current filter
There are no more items matching the current filter
Back to top